PDCD1 and non-small cell lung carcinoma: Furthermore, a correlation between Yes and increased presence of Tregs was observed in non-small cell lung cancer [144], and combined treatment with Dasatinib and anti-PD1 resulted in synergistic inhibition of tumor growth, which was accompanied by a reduction in Tregs and was dependent on the presence of CD4+ and CD8+ T cells.